Skip to main content
Premium Trial:

Request an Annual Quote

Mirus, Fugent Settle Patent Litigation

NEW YORK (GenomeWeb News) – Mirus Biosciences and Fugent have settled a lawsuit in which Mirus alleged Fugent infringed on a patent covering a method for gene transfer.

Fugent said in a statement today that the litigation was "resolved to Fugent's satisifaction and with no monetary compensation or other damages being paid by Fugent to Mirus." Mirus had asked for treble damages and attorney's fees in its complaint.

Fugent will now be able to commercialize its Fugene 6 and Fugene HD product without legal challenge by Mirus, Fugent said.

Fugene 6 and Fugene HD products are distributed by Promega.

Mirus did not respond to a request for comment.

Mirus sued Fugent in September in US District Court, Western District of Wisconsin, claiming Fugent, in particular its Fugene 6 transfection agent, infringed on US Patent Number 5,744,335, held by Mirus.

According to the patent's abstract, the invention provides a method for transfecting a cell with a polynucleotide mixed with amphipathic compounds and DNA-binding protein.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.